Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27991741 | 0.87 | ESR1 (0.44) | ESR1HTR7KDM4EHTR1BCHRNB2 | |
| SCHEMBL27458021 | 0.81 | MAPT (0.40) | ESR1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27639454 | 0.80 | HTR7 (0.44) | HTR7KDM4EHTR1BALDH1A1DRD2 | |
| SCHEMBL2479633 | 0.80 | HTR7 (0.53) | HTR7KDM4EHTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL4577229 | 0.80 | HTR7 (0.53) | HTR7KDM4EHTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL28551358 | 0.80 | ROCK2 (0.45) | HTR7KDM4EHTR1BALDH1A1SMN1; SMN2 | |
| SCHEMBL188778 | 0.79 | KDM4E (0.53) | ESR1HTR7KDM4EHTR1BALDH1A1 | |
| SCHEMBL27944106 | 0.79 | ESR1 (0.43) | ESR1SMN1; SMN2 | |
| SCHEMBL19924945 | 0.79 | IDO1 (0.44) | ALDH1A1DRD2DRD4 | |
| SCHEMBL3463971 | 0.79 | HTR7 (0.42) | ESR1HTR7KDM4EHTR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | claimed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | claimed |
| WO-2021158792-A1 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-08-12 | — | — | WO | claimed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | claimed |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2019-08-01 | — | — | US | claimed |
| EP-3507290-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | Agios Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | claimed |
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | claimed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | claimed |
| WO-2018045071-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | AGIOS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | claimed |
| CN-104211632-B | 2 indolone derivatives with tyrosine-kinase enzyme inhibition activity and preparation method and application | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 2016-12-28 | — | — | CN | claimed |
| US-RE49934-E1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2024-04-23 | — | — | US | disclosed |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | SERVIER PHARMACEUTICALS LLC (US) | 2022-05-10 | — | — | US | disclosed |
| WO-2021158792-A1 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY DISEASES OR DISORDERS | AGIOS PHARMACEUTICALS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021023609-A1 | COMBINATION OF A TYPE I PROTEIN ARGININE METHYLTRANSFERASE (TYPE I PRMT) INHIBITOR AND A METHIONINE ADENOSYLTRANSFERASE II ALPHA (MAT2A) INHIBITOR | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-02-11 | — | — | WO | disclosed |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | Agios Pharmaceutical, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| EP-3507290-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | Agios Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10329298-B2 | Inhibitors of cellular metabolic processes | AGIOS PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | SERVIER PHARMACEUTICALS LLC | 2018-03-22 | — | — | US | disclosed |
| WO-2018045071-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | AGIOS PHARMACEUTICALS, INC. (US) | 2018-03-08 | — | — | WO | disclosed |
| CN-104211632-A | 2-Indolone derivative with tyrosine kinase inhibition activity, and preparation method and application thereof | INST RADIATION MED AMMS PLA | 2014-12-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10329298-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | ESR1 3411/4885HTR7 4448/4885KDM4E 1507/4885 |
| US-20190233424-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | ESR1 3411/4885HTR7 4448/4885KDM4E 1507/4885 |
| US-10800782-B2 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | ESR1 3411/4885HTR7 4448/4885KDM4E 1507/4885 |
| US-20180079753-A1 | INHIBITORS OF CELLULAR METABOLIC PROCESSES | MNAT1, MAT2A, PCK2 | ESR1 3411/4885HTR7 4448/4885KDM4E 1507/4885 |
| US-11325914-B1 | Inhibitors of cellular metabolic processes | MNAT1, MAT2A, PCK2 | ESR1 3411/4885HTR7 4448/4885KDM4E 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.